

Supplemental Table S3: Adverse events possibly probably or definitely related to dasatinib across all 28 cycles (maximum grade per patient)

Adverse event (AE)	AE grade (Number of patients)			Total number of patients with AE
	1	2	3	
Hematologic				
Anemia	3	6	1	10
Lymphocyte count decreased	2	5	1	8
Lymphocyte count increase		1		1
Neutrophil count decreased		1	1	2
Platelet count decreased	9	2	1	12
White blood cell decreased	3	1		4
Non-hematologic				
Abdominal distention	3	1		4
Abdominal pain	1			1
Alanine aminotransferase increased	3			3
Alkaline phosphatase increased	1			1
Anorexia/Appetite decreased	4			4
Aspartate aminotransferase increased	3	2		5
Back pain		1		1
Bilirubin increased	1			1
Bronchopulmonary hemorrhage	1			1
Colitis		1		1
Constipation		1		1
Cough	2			2
Dehydration		1		1
Diarrhea	3		1	4
Dysphagia		1		1
Dyspnea	1	1		2
Edema	3			3
Epistaxis	1			1
Fatigue	3	2		5
Fever	1			1
Headache		1		1
Hematuria			1	1
Hemoptysis	1			1
Hyperkalemia	1			1
Hypoalbuminemia	1			1
Hypocalcemia	2	4		6
Hypokalemia	2		2	4
Hypomagnesemia	2			2
Hyponatremia	2	1		3
Hypophosphatemia	2	4	1	7
Hypoxia			1	1
Malaise	1			1
Nausea	4	2		6
Non-cardiac chest pain	1			1
Pain in extremity	1			1
Pericardial effusion		3		3
Photosensitivity	1			1
Pleural effusion	1	2		3
Pleuritic pain	2			2
Pneumonitis			1	1
Pneumothorax	1			1

Rash acneiform	3			3
Skin ulceration	1			1
Soft tissue infection		1		1
Suprapubic distention	1			1
Tachypnea	1			1
Vomiting	4			4
Weight gain	1			1
Weight loss	1			1
Wheezing	1			1